The National Medical Products Administration (NMPA) conditionally approved the marketing of Pometamethasone Alpha for injection.
June 5, 2026
Source: drugdu
37
Recently, the National Medical Products Administration (NMPA) conditionally approved the marketing of Pometrazyne Alpha for Injection (trade name: Bojia Ning) submitted by Jiangsu Bejitech Biotechnology Co., Ltd. through the priority review and approval procedure. It is indicated for the treatment of bleeding in adult patients with congenital hemophilia A or B who have an inhibitor of coagulation factor VIII or IX >5 Bethesda units (BU). The marketing of this product provides a new treatment option for these patients .
https://mp.weixin.qq.com/s/Y059ZMm7OwCt2Y6y9d5Aqw
Copyright©2026 Ddu. All rights reserved.
Read more on
- Cinda leads the world, and Takeda’s 1.2 billion gamble is reaping the rewards. June 5, 2026
- The generic version of this drug, developed by 35 pharmaceutical companies, has had its market launch delayed by 5 years. June 5, 2026
- Pharmaceutical giant lays off more employees June 5, 2026
- Imported “new kidney disease drug” approved June 5, 2026
- A breakthrough for domestically produced IOLs! Another innovative device approved for market launch June 5, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
